ER、PR、HER-2/neu与乳腺癌新辅助化疗有效率的关系研究  

Study on relationship between the expressions of ER,PR,HER-2/neu and the effective rate of neoadjuvant chemotherapy of breast cancer

作　　者：李志华[1] 苏逢锡[1] 贾卫娟[1] 姚和瑞[2] 

机构地区：[1]中山大学附属第二医院乳腺肿瘤中心,广州510120 [2]中山大学附属第二医院肿瘤科,广州510120

出　　处：《岭南现代临床外科》2007年第5期339-342,共4页Lingnan Modern Clinics in Surgery

基　　金：广东省医学科研基金资助课题(A2005226);广东省科技计划资助课题(2006B36002010)

摘　　要：目的探讨乳腺癌患者ER、PR、HER-2/neu的表达及其与新辅助化疗有效率的关系及乳腺癌新辅助化疗敏感性的预测指标。方法采用免疫组化的方法检测160例乳腺癌新辅助化疗病人化疗前后ER、PR、HER-2/neu的表达情况,并评估其与乳腺癌新辅助化疗有效率的关系。结果160例乳腺癌新辅助化疗病例中,ER、PR阴性率、HER-2/neu过度表达率分别为35.63%,24.38%,33.13%,ER(+)组与ER(-)组、PR(+)组与PR(-)组及HER-2/neu过度表达组与非过度表达组化疗有效率差异均有统计学意义(χ2>3.875,P<0.05);新辅助化疗前后ER、PR的阳性率和HER-2/neu过度表达率的改变无统计学意义。结论ER或PR阴性的乳腺癌病人对化疗更敏感,化疗后获益更多,而HER-2/neu过度表达的病人化疗不敏感,ER、PR和HER-2/neu可作为乳腺癌新辅助化疗敏感性的预测指标;新辅助化疗不改变ER、PR及HER-2/neu的表达水平。Objective To investigate the relationship between the expressions of ER, PR and HER-2/neu with the effective rate of neoadjuvant chemotherapy for breast cancer,and investigate the predictive index on neoadjuvant chemotherapy for breast cancer. Methods Expression of ER, PR and HER-2/neu in breast cancer of 160 patients received neoadjuvant chemotherapy were detected by immunohistochemical method before and after chemotherapy. The relationships of the expression levels and the effective rate were evaluated. Results Among the 160 cases of neoadjvant chemotherapy , the percentage of negative for ER, PR and over expression for HER-2/neu were 35.63%, 24.38%, 33.13% respectively. In the differences of chemotherapeutic effective rate between ER negative （-） and ER positive （＋）, PR negative （-） and PR positive（＋）, HER-2/neu over-expressed group and HER-2 non over-expressed group, there were statistical significance （X^2 〉 3.875, P〈0.05）.The change of ER, PR and HER-2/neu over expression after neoadjuvant chemotherapy didn＇t have statistical significance. Conclusion In the patients with breast cancer, ER or PR negative is more sensitive to chemotherapy. These patients may get more benefits from chemotherapy. The patients with HER-2/neu over expressed are easily resistant to chemotherapy. ER, PR and HER-2/neu can be considered ,as predictive markers of the effective rate of neoadjuvant chemotherapy expression of ER, PR and HER-2/neu. Neoadjuvant chemotherapy doesn＇t change the

关 键 词：乳腺癌 新辅助化疗 雌激素受体 孕激素受体 表皮生长因子受体-2 

分 类 号：R737.9[医药卫生—肿瘤]